Study: Theranos Tests Differed Enough To Throw Off Medical Decisions
The study concluded that Theranos’ results for total cholesterol were lower by an average of 9.3 percent than those produced by Quest and LabCorp.
The Wall Street Journal:
Theranos Results Could Throw Off Medical Decisions, Study Finds
A study by researchers at the Icahn School of Medicine at Mount Sinai showed that results for cholesterol tests done by Theranos Inc. differed enough from the two largest laboratory companies in the U.S. that they could throw off doctors’ medical decisions. The Mount Sinai study was published online Monday in the peer-reviewed Journal of Clinical Investigation. The authors recruited 60 healthy adults in the Phoenix area and sent them for 22 commonly prescribed blood tests over a five-day period in July 2015. (Carreyrou, 3/28)
In other news, San Diego-based Trovagene has a shake-up at the highest levels —
Biotech Trovagene Fires, Sues Its CEO, CFO; Shares Tumble
Trovagene Inc., maker of cancer-DNA detection and monitoring tests, said it fired and sued its chief executive officer and chief financial officer. The shares plunged in extended trading. Thomas Adams, Trovagene’s chairman, will be interim CEO, succeeding Antonius Schuh, the San Diego-based company said Monday in a statement. (Chen, 3/28)